<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01595828</url>
  </required_header>
  <id_info>
    <org_study_id>NK-104-4.03EU</org_study_id>
    <nct_id>NCT01595828</nct_id>
  </id_info>
  <brief_title>Effects of Pitavastatin on Monocyte, Endothelial Dysfunction and HDL-C in Subjects With Metabolic Syndrome</brief_title>
  <acronym>CAPITAIN</acronym>
  <official_title>An Open Label Study of the Chronic and Acute Effects of Pitavastatin on Monocyte Phenotype, Endothelial Dysfunction and HDL Atheroprotective Function in Subjects With Metabolic Syndrome (CAPITAIN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kowa Research Europe</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kowa Research Europe</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine in detail the acute and chronic effects of
      pitavastatin on plasma lipid transport and atheroma biomarkers in patients at elevated risk
      for the premature development of atherosclerosis (CAPITAIN).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline to Day 180 in plasma biomarkers of inflammation and atherosclerosis, including monocytes, lymphocytes, endothelial adhesion proteins, atherogenic lipoproteins and cardioprotective HDL</measure>
    <time_frame>180 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Pitavastatin 4mg daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 mg tablets of pitavastatin by oral route for a period of 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pitavastatin</intervention_name>
    <arm_group_label>Pitavastatin 4mg daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with metabolic syndrome

          -  Patients with LDL-C &gt; 130mg/dL

          -  Eligible, able to participate and have given informed consent

        Exclusion Criteria:

          -  Body Mass Index &gt;35 kg/m2

          -  LDL-C &gt; 190mg/dL

          -  Fasting triglycerides &gt; 400 mg/dL

          -  Diabetes mellitus (fasting glucose &gt;7 mmol/L) or taking diabetic therapy

          -  Uncontrolled hypertension (Systolic Blood Pressure &gt;= 140 mmHg or Diastolic Blood
             Pressure &gt;= 90mmHg)

          -  Any conditions that cause secondary dyslipidaemia or increase the risk of statin
             therapy

          -  ALAT and ASAT &gt;3 x ULRR

          -  Impaired renal function (Serum Creatinine &gt;1.5 x ULRR or eGFR &lt;60 mL/min)

          -  History of any muscle disease or unexplained elevation (&gt;3 x ULRR) of serum creatine
             kinase

          -  Evidence of symptomatic heart failure (NYHA class III or IV)

          -  Current or recent user of supplements or medications known to alter lipid metabolism
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kowa Research Europe Ltd.</name>
      <address>
        <city>Wokingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2012</study_first_submitted>
  <study_first_submitted_qc>May 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2012</study_first_posted>
  <last_update_submitted>July 19, 2013</last_update_submitted>
  <last_update_submitted_qc>July 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pitavastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

